Helex
Helex is a biotechnology company developing next-generation gene-editing therapies for genetic kidney diseases, starting with Autosomal Dominant Polycystic Kidney Disease (ADPKD). The company's proprietary lipid nanoparticle technology enables targeted delivery of therapeutic cargo to the kidney, while its pioneering Epic-Cure technology ensures de-risked drug design for greater precision and safety of genetic…
Funding snapshot
About
Helex is a biotechnology company developing next-generation gene-editing therapies for genetic kidney diseases, starting with Autosomal Dominant Polycystic Kidney Disease (ADPKD). The company's proprietary lipid nanoparticle technology enables targeted delivery of therapeutic cargo to the kidney, while its pioneering Epic-Cure technology ensures de-risked drug design for greater precision and safety of genetic medicines by avoiding unwanted editing in non-target cells and tissues. Helex leverages data, machine learning, and epigenetics to reduce trial and error in designing gene editing-based drugs, targeting over 700 million people worldwide suffering from chronic kidney disease. The company has been recognized by NIH as a winner of Phase 2 of the TARGETED Genome Editor Delivery Challenge and has presented at ASN Kidney Week, ESGCT Annual Meeting, and ASGCT. Founded in 2021 and headquartered in New York City with operations in Hyderabad, India, Helex has raised $6M in seed funding from investors including IndieBio, Bluehill VC, pi Ventures, and SOSV.
Business model
Nephrology > Drugs > Chronic Kidney Diseases,
Drug Delivery > Nanoparticle Based,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Founders & team highlights
Founder with Prior Funding,
Serial Founder
Team background
Top Rated Teams > Serial Entrepreneur,
College Wise > King’s College London
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.